![]() |
Treating Sports Injuries: Part 2
|
![]() |
Treating Sports Injuries: Part 1
|
![]() |
Treating Sports Injuries: Part 3
|
Analgesics are medicines that relieve pain.
Analgesics are those drugs whose primary purpose is pain relief. The primary classes of analgesics are the narcotics, including additional agents that are chemically based on the morphine molecule but have minimal abuse potential; nonsteroidal anti-inflammatory drugs (NSAIDs) including the salicylates; and acetaminophen. Other drugs, notably the tricyclic antidepressants and anti-epileptic agents such as gabapentin, have been used to relieve pain, particularly neurologic pain, but are not routinely classified as analgesics. Analgesics provide symptomatic relief, but have no effect on causation, although clearly the NSAIDs, by virtue of their dual activity, may be beneficial in both regards.
Pain has been classified as "productive" pain and "non-productive" pain. While this distinction has no physiologic meaning, it may serve as a guide to treatment. "Productive" pain has been described as a warning of injury, and so may be both an indication of need for treatment and a guide to diagnosis. "Non-productive" pain by definition serves no purpose either as a warning or diagnostic tool.
Although pain syndromes may be dissimilar, the common factor is a sensory pathway from the affected organ to the brain. Analgesics work at the level of the nerves, either by blocking the signal from the peripheral nervous system, or by distorting the interpretation by the central nervous system. Selection of an appropriate analgesic is based on consideration of the risk-benefit factors of each class of drugs, based on type of pain, severity of pain, and risk of adverse effects. Traditionally, pain has been divided into two classes, acute and chronic, although severity and projected patient survival are other factors that must be considered in drug selection.
Acute pain is self limiting in duration, and includes post-operative pain, pain of injury, and childbirth. Because pain of these types is expected to be short term, the long-term side effects of analgesic therapy may routinely be ignored. Thus, these patients may safely be treated with narcotic analgesics without concern for their addictive potential, or NSAIDs with only limited concern for their ulcerogenic risks. Drugs and doses should be adjusted based on observation of healing rate, switching patients from high to low doses, and from narcotic analgesics to non-narcotics when circumstances permit.
An important consideration of pain management in severe pain is that patients should not be subject to the return of pain. Analgesics should be dosed adequately to assure that the pain is at least tolerable, and frequently enough to avoid the anxiety that accompanies the anticipated return of pain. Analgesics should never be dosed on a "prn" (as needed) basis, but should be administered often enough to assure constant blood levels of analgesic. This applies to both the narcotic and non-narcotic analgesics.
| Opioid analgesics | ||||||
| Route of | Onset of | Duration of | ||||
| Drug | administration | action (min) | action (h) | |||
| IM= intramuscular; IV = intravenous; sub-Q = subcutaneous | ||||||
| SOURCE: Ciccone, C.D. Pharmacology in Rehabilitation. 2nd ed. Philadelphia: F.A. Davis Co., 1996. | ||||||
| Strong agonists | ||||||
| Fentanyl (Sublimaze) | IM | 7–15 | 1–2 | |||
| IV | 1–2 | 0.5–1 | ||||
| Hydromorphone Oral | 30 | 4 | ||||
| (Dilaudid) | IM | 15 | 4 | |||
| IV | 10–15 | 2–3 | ||||
| Sub-Q | 15 | 4 | ||||
| Levorphanol Oral | 10–60 | 4–5 | ||||
| (Levo-Dromoran) | IM | — | 4–5 | |||
| IV | — | 4–5 | ||||
| Sub-Q | — | 4–5 | ||||
| Meperidine (Demerol) | Oral | 15 | 2–4 | |||
| IM | 10–15 | 2–4 | ||||
| IV | 1 | 2–4 | ||||
| Sub-Q | 10–15 | 2–4 | ||||
| Methadone (Dolophine) | Oral | 30–60 | 4–6 | |||
| IM | 10–20 | 4–5 | ||||
| IV | — | 3–4 | ||||
| Morphine Oral | — | 4–5 | ||||
| (many trade names) | IM | 10–30 | 4–5 | |||
| IV | — | 4–5 | ||||
| Sub-Q | 10–30 | 4–5 | ||||
| Epidural | 15–60 | up to 24 | ||||
| Oxymorphone IM | 10–15 | 3–6 | ||||
| (Numorphan) | IV | 5–10 | 3–4 | |||
| Sub-Q | 10–20 | 3–6 | ||||
| Rectal | 15–30 | 3–6 | ||||
| Mild-to-moderate agonists | ||||||
| Codiene Oral | 30–40 | 4 | ||||
| (many trade names) | Im | 10–30 | 4 | |||
| Sub-Q | 10–30 | 4 | ||||
| Hydrocodone (Hycodan) | Oral | 10–30 | 4–6 | |||
| Oxycodone (Percodan) | Oral | — | 3–4 | |||
| Propoxyphene | ||||||
| (Darvon, Dolene) | Oral | 15–60 | 4–6 | |||
| Butophanol (Stadol) | IM | 10–30 | 3–4 | |||
| IV | 2–3 | 2–4 | ||||
| Nalbuphine (Nubian) | IM | within 15 | 3–6 | |||
| IV | 2–3 | 3–4 | ||||
| Sub-Q | within 15 | 3–6 | ||||
| Pentazocine (Talwin) | Oral | 15–30 | 3 | |||
| IM | 15–20 | 2–3 | ||||
| IV | 2–3 | 2–3 | ||||
| Sub-Q | 15–20 | 2–3 | ||||
|
|
Author Info: Samuel Uretsky PharmD, The Gale Group Inc., Gale, Detroit, Gale Encyclopedia of Nursing and Allied Health, 2002 |